Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax and Quizartinib in FLT3-mutated AML
NCT03735875Phase 2Terminated
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jan 2019
- Primary completion
- Jul 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of venetoclax, quizartinib in acute myeloid leukemia (AML), sponsored by University of Texas MD Anderson Cancer Center. Started Jan 2019; status: terminated.
02
Drugs
venetoclaxquizartinib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT03735875.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03735875.